← Leaderboards
Tina Cascone
University Of Tx Md Anderson Can Ctr
$2,250,345
Attributed
$4,500,689
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,500,689 · 2
By mechanism
R01$4,500,689 · 2
Top collaborators
- Jia Wu5 shared
- Humam Kadara2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Hesham M Amin$3,011,396
- Ahmed Kaseb$3,699,074
- Cielito C Reyes-Gibby$3,873,330
- Heath Devin Skinner$8,539,031
- Natalie Vokes$989,037
Others in their field
Other Emerging Leaders on “Maps”
- Jacob Ruff · Cornell University$22,500,000
- Leonard Freedman · Leidos Biomedical Research, Inc.$21,750,066
- Rui M. Costa · Columbia University Health Sciences$19,333,042
- Peter John Hunter · University Of Auckland$16,320,924
- Badri N Vardarajan · University Of Miami School Of Medicine$16,083,856
- Andrew Shoffstall · Louis Stokes Cleveland Va Medical Center$15,790,088
Research focus
MapsPre-ClinicalImmunotherapyMalignant Neoplasm Of LungPhenotypePathologicImmuneImmunogenomicsLeadLungNeoplasm MetastasisNeoadjuvant TherapyNon-Small-Cell Lung CarcinomaNovel TherapeuticsAdjuvantClinical EffectivenessImmune Checkpoint InhibitorImmuno-ChemotherapyCohortImproved OutcomeClinical PracticeClinical TrialsMouse ModelPre-Clinical Model
Grant awards (7)
Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy$670,358
R01 · FY2025 · CA · contact PI
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer$606,797
R01 · FY2025 · CA
Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy$670,358
R01 · FY2024 · CA · contact PI
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer$609,048
R01 · FY2024 · CA
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer$658,205
R01 · FY2023 · CA
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer$661,394
R01 · FY2022 · CA
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer$624,529
R01 · FY2021 · CA